CytoSorbents (NASDAQ: CTSO) strikes deal to cut loan principal by 30.0%

What happened

CytoSorbents Corporation (NASDAQ: CTSO) agreed to a $6.25 million financing that would pay down its Avenue Capital Group loan with cash and stock. The planned repayments would cut principal from $17.5 million before the Nov. 19 agreement to $12.25 million, a 30.0% drop, OptimistFi calculates.

Shareholders face dilution in exchange for lower borrowing costs. The registered direct offering of shares and pre-funded warrants would raise about $4 million before expenses and about $3.5 million after them. Existing shareholders, management and directors subscribed for about three-quarters of the offering.

Most of the net proceeds would go to Avenue Capital Group. CytoSorbents plans to repay $3 million of principal in cash and make a $52,500 prepayment fee payment and a $270,000 final payment. Avenue Venture Opportunities Fund, L.P. would take 455,465 shares in exchange for $2.25 million of principal.

Key numbers

Metric Latest Change Source
Announced common stock financing, including the debt exchange $6.25 million CytoSorbents press release
Expected gross cash proceeds About $4 million CytoSorbents press release
Estimated net offering proceeds About $3.5 million SEC 8-K
Expected reduction in loan principal $5.25 million CytoSorbents press release
Expected remaining loan principal $12.25 million CytoSorbents press release
Expected interest savings over 12 months About $700,000 CytoSorbents press release

Read more: CytoSorbents (CTSO) company research

Why it matters

CytoSorbents expects to save about $700,000 in interest over 12 months. The amendment moves the due date from July 1, 2027, to July 1, 2028, and extends interest-only payments through March 31, 2028.

The amendment also gives CytoSorbents more room under its cash-burn covenant. The threshold rises to $3.2 million for testing periods through Dec. 31 and is $2 million otherwise.

Further debt relief could dilute shareholders again. Lenders can convert part of the principal into stock at $6.92 a share. They can convert another portion at $8.65 a share starting Jan. 1, 2028, or sooner if the FDA grants marketing approval for DrugSorb-ATR.

In OptimistFi's view, the lower debt load helps, but CytoSorbents still needs wider use of its blood purification devices in intensive care and cardiac surgery to outpace cash burn.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The offering is expected to close on or about Nov. 20 if standard closing conditions are met. The principal will fall only once CytoSorbents makes the cash repayment and completes the stock exchange. Both are expected around the same time as the offering close.

More from OptimistFi

From OptimistFi Perps

Sources

  • CytoSorbents press release — Nov. 20, 2026 announcement of the common stock financing and the loan restructuring with Avenue Capital Group.
  • SEC 8-K — Reports the Nov. 19, 2026 agreements, estimated net proceeds and revised loan terms.

Explore OptimistFi research on CytoSorbents Corporation: https://optimistfi.com/stocks/CTSO

Browse CytoSorbents Corporation company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the CytoSorbents Corporation company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.